Related Experiment Video
Updated: Jan 24, 2026

Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with
Mark N Stein1,2, Jyoti Malhotra2, Rohinton S Tarapore3
1Division of Hematology/Oncology, Columbia University Medical Center, New York, NY, USA.
Background:
ONC201 is a small molecule antagonist of DRD2, a G protein-coupled receptor overexpressed in several malignancies, that has prolonged antitumor efficacy and immunomodulatory properties in preclinical models. The first-in-human trial of ONC201 previously established a recommended phase II dose (RP2D) of 625 mg once every three weeks. Here, we report the results of a phase I study that evaluated the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of weekly ONC201.
Methods:
Patients ≥ 18 years old with an advanced solid tumor refractory to standard treatment were enrolled. Dose escalation proceeded with a 3 + 3 design from 375 mg to 625 mg of ONC201. One cycle, also the dose-limiting toxicity (DLT) window, was 21 days. The primary endpoint was to determine the RP2D of weekly ONC201, which was confirmed in an 11-patient dose expansion cohort.
Results:
Twenty patients were enrolled: three at 375 mg and 17 at 625 mg of ONC201. The RP2D was defined as 625 mg with no DLT, treatment discontinuation, or dose modifications due to drug-related toxicity. PK profiles were consistent with every-three-week dosing and similar between the first and fourth dose. Serum prolactin and caspase-cleaved cytokeratin-18 induction were detected, along with intratumoral integrated stress response activation and infiltration of granzyme B+ Natural Killer cells. Induction of immune cytokines and effectors was higher in patients who received ONC201 once weekly versus once every three weeks. Stable disease of > 6 months was observed in several prostate and endometrial cancer patients.
Conclusions:
Weekly, oral ONC201 is well-tolerated and results in enhanced immunostimulatory activity that warrants further investigation.
Trial Registration:
NCT02250781 (Oral ONC201 in Treating Patients With Advanced Solid Tumors), NCT02324621 (Continuation of Oral ONC201 in Treating Patients With Advanced Solid Tumors).
Insights
Weekly oral ONC201, a DRD2 antagonist, is safe and well-tolerated in advanced solid tumors. This dosing schedule enhances anti-tumor immune responses, showing promise for future cancer therapies.
Area of Science:
- Oncology
- Pharmacology
- Immunology
Background:
- ONC201 is a small molecule antagonist targeting DRD2, a receptor overexpressed in various cancers.
- Preclinical studies demonstrated ONC201's antitumor efficacy and immunomodulatory effects.
- Previous trials established a recommended Phase II dose (RP2D) of 625 mg every three weeks.
Purpose of the Study:
- To evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of weekly ONC201 administration.
- To determine the RP2D for a weekly dosing schedule of ONC201 in patients with advanced solid tumors.
- To assess the immunomodulatory effects of weekly ONC201 compared to every-three-week dosing.
Main Methods:
- A Phase I dose-escalation study using a 3+3 design enrolled patients aged 18+ with advanced solid tumors refractory to standard treatments.
- Dose levels ranged from 375 mg to 625 mg of ONC201, with a 21-day cycle and dose-limiting toxicity (DLT) window.
- A dose expansion cohort of 11 patients confirmed the RP2D for weekly ONC201.
Main Results:
- Twenty patients were enrolled; the RP2D was determined to be 625 mg weekly, with no DLTs, treatment discontinuations, or dose modifications due to toxicity.
- PK profiles were consistent with established every-three-week dosing and remained stable between the first and fourth doses.
- Weekly ONC201 induced serum prolactin, caspase-cleaved cytokeratin-18, integrated stress response, and Natural Killer cell infiltration; immune responses were heightened compared to every-three-week dosing.
- Stable disease for over six months was observed in some prostate and endometrial cancer patients.
Conclusions:
- Weekly oral administration of ONC201 is well-tolerated in patients with advanced solid tumors.
- The weekly schedule enhances immunostimulatory activity compared to less frequent dosing.
- These findings support further investigation of weekly ONC201 in clinical trials for cancer treatment.
Related Concept Videos
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Cholinergic Antagonists: Chemistry and Structure-Activity Relationship
Survey Safety
Metallic Solids
All metallic solids exhibit high thermal and electrical conductivity, metallic luster, and malleability....
Structures of Solids

